Levine, Bruce L.

A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies

Wang, K., Liu, Y., Li, J., Wang, B., Bishop, R., White, C., Das, A., Levine, A. D., Ho, L., Levine, B. L., et al. (2019) · Cytotherapy

Simulation Techniques and ApplicationsSupply Chain and Inventory Management

Cited by 29

Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in non-Hodgkin lymphoma (NHL)

Davis, M. M., Fesnak, A., Leskowitz, R. M., McKee, J. S., Ohayon, Y., Corl, C. M., Malykhin, A., Fraietta, J. A., Joseph Melenhorst, J., June, C., et al. (2017) · Cytotherapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 11

Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).

Schuster, S. J., Svoboda, J., Nasta, S., Chong, E. A., Porter, D. L., Landsburg, D. J., Mato, A. R., Bhoj, V. G., Milone, M., Lacey, S. F., et al. (2016) · Journal of Clinical Oncology

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 10

Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming

Rapoport, A., Stadtmauer, E., Melchiori, L., Wong, R., Davila, E., Binder-Scholl, G., Holdich, T., Vogl, D., Weiss, B., Finkelstein, J., et al. (2015) · Cancer Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1